一文汇总丨非酒精性脂肪性肝病相关HCC的危险因素与预防策略
NAFLD相关HCC的危险因素
NAFLD相关HCC的预防
小结
*肝癌在线原创编译
1. Yang, J. D. et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology 71, 907–916 (2020).
2. Alexander, M. et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 17, 95 (2019).
3. Davila, J. A., Morgan, R. O., Shaib, Y., McGlynn, K. A. & El-Serag, H. B. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 54, 533–539 (2005).
4. El-Serag, H. B., Hampel, H. & Javadi, F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin. Gastroenterol. Hepatol. 4, 369–380 (2006).
5. Kanwal, F. et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology 71, 808–819 (2020). In this study of 271,906 patients with NAFLD diagnosed between 2004 and 2008, diabetes had the strongest association with HCC development (adjusted HR 2.77, 95% CI 2.03–3.77) among the metabolic risk factors.
6. Chen, Y., Wang, X., Wang, J., Yan, Z. & Luo, J. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur. J. Cancer 48, 2137–2145 (2012).
7. Hassan, M. M. et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology 149, 119–129 (2015).
8. Nair, S., Mason, A., Eason, J., Loss, G. & Perrillo, R. P. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 36, 150–155 (2002).
9. Petrick, J. L. et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project. Br. J. Cancer 118, 1005–1012 (2018).
10. Abdel-Rahman, O. et al. Cigarette smoking as a risk factor for the development of and mortality from hepatocellular carcinoma: an updated systematic review of 81 epidemiological studies. J. Evid. Based Med. 10, 245–254 (2017).
11. Ascha, M. S. et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).
12. Miele, L. et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887 (2009).
13. Zhang, H.-L. et al. Profound impact of gut homeostasis on chemically-induced pro-tumorigenic inflammation and hepatocarcinogenesis in rats. J. Hepatol. 57, 803–812 (2012).
14. Sharpton, S. R., Ajmera, V. & Loomba, R. Emerging role of the gut microbiome in nonalcoholic
fatty liver disease: from composition to function. Clin. Gastroenterol. Hepatol. 17, 296–306 (2019).
15. Luther, J. et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal permeability. Cell. Mol. Gastroenterol. Hepatol. 1, 222–232 (2015).
16. Gäbele, E. et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J. Hepatol. 55, 1391–1399 (2011).
17. Makishima, M. et al. Identification of a nuclear receptor for bile acids. Science 284, 1362–1365 (1999).
18. Meng, Z. et al. FXR regulates liver repair after CCl4-induced toxic injury. Mol. Endocrinol. 24, 886–897 (2010).
19. Yang, F. et al. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 67, 863–867 (2007).
20. Fickert, P. et al. Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. Am. J. Pathol. 175, 2392–2405 (2009).
21. Ponziani, F. R. et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology 69, 107–120 (2019). This study from Italy demonstrated that Akkermansia and Bifidobacterium species are decreased in patients with NAFLD-related HCC compared with patients with NASH cirrhosis, highlighting that dysregulation of the gut microbiome might influence NAFLD-related hepatocarcinogenesis.
22. Wu, W. et al. Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model. Front. Microbiol. 8, 1804 (2017).
23. Fang, D. et al. Bifidobacterium pseudocatenulatum LI09 and Bifidobacterium catenulatum LI10 attenuate D-galactosamine-induced liver injury by modifying the gut microbiota. Sci. Rep. 7, 8770 (2017).
24. Stender, S. & Loomba, R. PNPLA3 genotype and risk of liver and all-cause mortality. Hepatology 71, 777–779 (2020).
25. Singal, A. G. et al. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. Am. J. Gastroenterol. 109, 325–334 (2014).
26. Liu, Y.-L. et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J. Hepatol. 61, 75–81 (2014).
27. Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328–357 (2018).
28. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
29. Chitturi, S. et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017–Part 2: management and special groups. J. Gastroenterol. Hepatol. 33, 86–98 (2018).
30. Vilar-Gomez, E. et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 149, 367–378.e5 (2015).
31. Demierre, M.-F., Higgins, P. D. R., Gruber, S. B., Hawk, E. & Lippman, S. M. Statins and cancer prevention. Nat. Rev. Cancer 5, 930–942 (2005).
32. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology 144, 323–332 (2013).
33. Thrift, A. P., Natarajan, Y., Liu, Y. & El-Serag, H. B. Statin use after diagnosis of hepatocellular carcinoma is associated with decreased mortality. Clin. Gastroenterol. Hepatol. 17, 2117–2125.e3 (2019).
34. Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE 7, e29849 (2012).
35. Singh, S., Singh, P. P., Singh, A. G., Murad, M. H. & Sanchez, W. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis. Am. J. Gastroenterol.108, 881–891 (2013).
36. Ma, S., Zheng, Y., Xiao, Y., Zhou, P. & Tan, H. Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. Medicine 96, e6888 (2017).
37. Zhou, Y.-Y. et al. Systematic review with network meta-analysis: antidiabetic medication and risk of hepatocellular carcinoma. Sci. Rep. 6, 33743 (2016).
38. Tseng, C.-H. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int. 38, 2018–2027 (2018).
39. Sitia, G. et al. Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc. Natl Acad. Sci. USA 109, E2165–E2172 (2012).
40. Sahasrabuddhe, V. V. et al. Nonsteroidal antiinflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J. Natl Cancer Inst. 104, 1808–1814 (2012).
41. Simon, T. G. et al. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 4, 1683–1690 (2018).